Prodrugs of NSAIDs: A Review

Kamal Shah1, *, Jeetendra K. Gupta1, Nagendra S. Chauhan4, Neeraj Upmanyu2, Sushant K. Shrivastava3, Pradeep Mishra1
1 Institute of Pharmaceutical Research, GLA University, Mathura, U.P.- 281406, India
2 School of Pharmacy & Research, Peoples University, Bhopal, M.P.- 462037, India
3 Department of Pharmaceutics, Institute of Technology, Banaras Hindu University, Varanasi U.P.- 221005, India
4 Drugs Testing Laboratory Avam Anusandhan Kendra,Raipur (CG),India

Article Metrics

CrossRef Citations:
Total Statistics:

Full-Text HTML Views: 4129
Abstract HTML Views: 642
PDF Downloads: 634
ePub Downloads: 346
Total Views/Downloads: 5751
Unique Statistics:

Full-Text HTML Views: 1978
Abstract HTML Views: 369
PDF Downloads: 485
ePub Downloads: 239
Total Views/Downloads: 3071

Creative Commons License
© 2017 Shah et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4. 0 International Public License (CC-BY 4. 0), a copy of which is available at: https://creativecommons. org/licenses/by/4. 0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this authors at the Department of Pharmaceutical Chemistry, Institute of Pharmaceutical Research, GLA University, NH # 2, Delhi-Mathura Road, Post: Chaumuhan, Mathura (UP) India 281406; Tel: +91 9359059129; Fax: +91 5662 241218; E-mail:



Prodrug approach deals with chemical biotransformation or enzymatic conversion or involves inactive or less active bio-reversible derivatives of active drug molecules. They have to pass through enzymatic or chemical biotransformation before eliciting their pharmacological action.

Methods & Materials:

The two different pharmacophores combine to give synergistic activity or may help in targeting the active drug to its target. Prodrug super seeds the problems of prodrug designing, for example solubility enhancement, bioavailability enhancement, chemical stability improvement, presystemic metabolism, site specific delivery, toxicity masking, improving patient acceptance, or eradicating undesirable adverse effects.


As an outcome the search for a prodrug or mutual prodrug with reduced toxicity has continued during recent years. This present review emphasizes the common help to revamp physiochemical, pharmaceutical and therapeutic effectiveness of drugs.


This gives the researcher a common platform where they can find prodrugs of commonly used NSAIDs to overcome the gastrointestinal toxicity (irritation, ulcergenocity and bleeding).

Keywords: Prodrug, Synergistic, NSAIDs, Ulcergenocity, Gastrointestinal toxicity, Enzymatic attack.